Comparative Pharmacology
Head-to-head clinical analysis: NEOSAR versus VALCHLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOSAR versus VALCHLOR.
NEOSAR vs VALCHLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that inhibits DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis.
Valchlor (mechlorethamine) is a nitrogen mustard alkylating agent that forms cross-links between DNA strands, leading to inhibition of DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
Cyclophosphamide 500-1500 mg/m² IV every 2-4 weeks; oral 50-200 mg daily.
Topical: Apply 0.016% mechlorethamine gel to affected areas once daily.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours; prolonged in hepatic impairment (up to 12 hours).
The terminal elimination half-life is approximately 24 hours after topical application, supporting daily dosing. Systemic half-life may be prolonged in patients with hepatic impairment.
Renal: 30-60% unchanged; biliary/fecal: 10-20% as metabolites.
Following topical application, VALCHLOR (mechlorethamine) is systemically absorbed; approximately <10% is excreted unchanged in urine. The majority of the dose is eliminated via metabolism and biliary/fecal routes, with ~50% of a systemic dose recovered in feces as metabolites.
Category C
Category C
Alkylating Agent
Alkylating Agent